Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
Poolbeg Pharma (POLB.L) agrees terms to develop an oral vaccine delivery platform
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,
Poolbeg Pharma PLC (POLB.L) signs option for new vaccine candidate
Poolbeg signs Option Agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets
Poolbeg Pharma PLC (POLB.L) Scientific Advisory Board Appointment
US infectious diseases expert, Professor Daniel Hoft, joins Scientific Advisory Board 25 November 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a
Poolbeg Pharma PLC (POLB.L) Update on POLB 001 Clinical Development
Rapidly progressing towards LPS challenge study
Sareum Holdings PLC (SAR.L) US Patent Notice of Allowance for SDC-1802
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Sareum Holdings PLC (SAR.L) Covid-19 Research Project Results
Completed Covid-19 Research Project Delivers Encouraging Results
Braveheart Inv Group (BRH.L) Further update re Paraytec Limited
Further to the announcement on 4 May 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
Braveheart Inv Group (BRH.L) Final Results for the year ended 31 March 2021 & Notice of AGM
Braveheart Investment Group plc (AIM: BRH) announces its audited annual results for the financial year ended 31 March 2021, highlights of which are set out below:
Braveheart Inv Group (BRH.L) Further update re Paraytec Limited
Further to the announcements on 29 January 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
Braveheart Inv Group (BRH.L) Special Dividend
In the interim results for the six months ended 30 September 2020, the board of Braveheart (the “Board”) announced that it had declared the payment of a special interim dividend
Braveheart Inv Group (BRH.L) Share transactions in Remote Monitored Systems plc
Braveheart announces that on 18 November 2020, it sold a total of 112,592,405 ordinary shares in Remote Monitored System plc (“RMS”).